Fredric D. Price

Fredric D. Price was elected executive chairman of the board of directors in August 2007. Mr. Price is also the chairman of the Board of Directors of Omrix Biopharmaceuticals (NASDAQ: OMRI), a member of the Board of Directors of Enobia Pharma, and a member of the Board of Directors of Pharmasset (NASDAQ: VRUS). Previously, he was CEO and chairman of the Board of Directors of BioMarin Pharmaceuticals (NASDAQ: BMRN); and president, CEO, and a member of the Board of Directors of Applied Microbiology. As chairman and/or CEO, he has raised $500 million in a variety of securities transactions, built FDA-approved facilities, and had drugs approved in the United States as well as in international markets. His earlier experience includes having been vice president of finance and administration and chief financial officer of Regeneron Pharmaceuticals, the founder of the strategy consulting firm RxFDP, and vice president of Pfizer Pharmaceuticals with both line and staff responsibilities. Mr. Price is a co-inventor of twelve issued U.S. patents and one U.S. patent application. He received a BA from Dartmouth College and an MBA from the Wharton School of the University of Pennsylvania.